Its not that bad, but its not a good stock for retail to hold as they grow. When the orphan drug status was given retail thought it would be a juggernaut back up to the IPO price... when it did not they have sold as well as shorts have shorted it down.
Its a long term stock, and when drug approval happens then its a rocket to $8.00 I am buying as it dips and holding until the phase III trials are completed and approval comes their way.
News 
Market Data 
Discover 
